Palisade Bio, Inc. (PALI) Income Statement
PALI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPALI revenue and net income
PALI profit margins
PALI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PALI quarterly EPS vs estimates
Palisade Bio beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.06).
PALI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $250,000 | $250,000 | $0 | $13,520 | $15,394 | $260,000 | $260,000 | $16,246 |
| Cost of revenue | $3,000 | $3,000 | $4,000 | $167,000 | $168,000 | $146,000 | $0 | −$990,000 | $0 | $0 |
| Gross profit | −$3,000 | −$3,000 | $250,000 | −$167,000 | −$168,000 | −$146,000 | $15,394 | $1.2M | $260,000 | $16,246 |
| Research & development | $10.2M | $9.1M | $6.9M | $6.5M | $2.4M | $3.1M | $4.1M | $4.0M | $8.0M | $12.8M |
| Sales, general & admin | $7.9M | $5.8M | $6.2M | $8.8M | $9.3M | $6.2M | $7.3M | $4.4M | $5.8M | $8.0M |
| Total operating expenses | $18.1M | $14.9M | $13.3M | $15.7M | $41.9M | $9.2M | $8.6M | $8.5M | $13.6M | $20.7M |
| Operating income | −$18.1M | −$14.9M | −$13.1M | −$15.7M | −$41.9M | −$9.3M | −$8.6M | −$8.3M | −$13.2M | −$20.2M |
| Interest income | — | — | — | — | — | $28,810 | $557,950 | $3.3M | $1.6M | $422,210 |
| Interest expense | $10,000 | $12,000 | $15,000 | $13,000 | $2.4M | $235,000 | $8,920 | $7,698 | $159,066 | $1.1M |
| Income before taxes | −$16.8M | −$14.4M | −$12.3M | −$14.3M | −$26.6M | −$10.3M | −$8.4M | −$4.9M | −$15.7M | −$21.1M |
| Income taxes | — | — | $16,000 | −$1.5M | $655,000 | $248,000 | $288,963 | $3.3M | −$2.2M | $703,529 |
| Net income | −$16.8M | −$14.4M | −$12.3M | −$14.3M | −$26.6M | −$10.3M | −$8.4M | −$4.9M | −$15.7M | −$21.1M |
| EBITDA | −$16.8M | −$14.4M | −$12.3M | −$14.2M | −$24.2M | −$9.9M | −$8.2M | −$4.7M | −$15.2M | −$19.6M |
| EPS (diluted) | −$1.49 | −$10.92 | −$29.85 | −$157.59 | −$360.94 | −$13.42 | −$13.39 | −$3.94 | −$4740.36 | −$16680.00 |
| Gross margin | — | — | 100.0% | −66.8% | — | −1,079.9% | 100.0% | 480.8% | 100.0% | 100.0% |
| Operating margin | — | — | −5,228.0% | −6,288.4% | — | −68,764.8% | −56,073.8% | −3,176.5% | −5,082.7% | −124,135.2% |
| Net margin | — | — | −4,920.0% | −5,704.0% | — | −76,346.2% | −54,254.9% | −1,894.2% | −6,025.4% | −129,724.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $500,000 | $0 | $0 | $0 | $0 | $0 | $4,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | — | — | — | $1,000 | $1,000 | $2,000 | $1,000 | $1,000 | $1,000 | $54,000 | $1,000 |
| Gross profit | $500,000 | — | — | — | −$1,000 | −$1,000 | $2,000 | −$1,000 | −$1,000 | −$1,000 | −$304,000 | −$1,000 |
| Research & development | $7.4M | $6.4M | $6.2M | $1.4M | $1.7M | $950,000 | $2.1M | $2.1M | $2.6M | $2.2M | $1.4M | $2.1M |
| Sales, general & admin | $4.8M | $4.4M | $3.8M | $1.5M | $1.2M | $1.4M | $1.3M | $1.5M | $1.6M | $1.5M | $1.6M | $1.7M |
| Total operating expenses | $12.2M | $10.7M | $10.0M | $2.9M | $2.8M | $2.3M | $3.4M | $3.6M | $4.2M | $3.7M | $3.2M | $3.8M |
| Operating income | −$11.7M | −$10.7M | −$10.0M | −$2.9M | −$2.8M | −$2.3M | −$3.4M | −$3.6M | −$4.2M | −$3.7M | −$3.2M | −$3.8M |
| Interest expense | $0 | $1,000 | $2,000 | $5,000 | $2,000 | $1,000 | $3,000 | $6,000 | $2,000 | $1,000 | $4,000 | $8,000 |
| Income before taxes | −$10.6M | −$9.6M | −$8.9M | −$2.9M | −$2.8M | −$2.2M | −$3.3M | −$3.5M | −$4.1M | −$3.5M | −$3.0M | −$3.6M |
| Income taxes | — | — | — | — | — | — | — | — | −$1,000 | −$42,276 | −$32,000 | −$1,000 |
| Net income | −$10.6M | −$9.6M | −$8.9M | −$2.9M | −$2.8M | −$2.2M | −$3.3M | −$3.5M | −$4.1M | −$3.5M | −$3.0M | −$3.6M |
| EBITDA | −$10.6M | −$9.6M | −$10.2M | −$2.9M | −$2.8M | −$2.2M | −$3.3M | −$3.5M | −$4.1M | −$3.5M | −$2.9M | −$3.6M |
| EPS (diluted) | −$0.05 | −$0.05 | −$0.06 | −$0.38 | −$0.58 | −$0.47 | −$0.69 | −$2.32 | −$3.32 | −$4.59 | −$6.45 | −$7.35 |
| Gross margin | 100.0% | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | −2,339.6% | — | — | — | — | — | −84,550.0% | — | — | — | — | — |
| Net margin | −2,114.8% | — | — | — | — | — | −83,600.0% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PALI's financial statements (latest annual report filed March 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PALI financial results
Palisade Bio reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $16.8 million. Diluted earnings per share came to −$1.49.
See the PALI stock overview for the latest quote and news, or the PALI chart for price history and technical indicators.
PALI income statement FAQ
Does Palisade Bio have revenue?
Palisade Bio reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Palisade Bio profitable?
No. Palisade Bio reported a net loss of $16.8 million in fiscal 2025.
How much does Palisade Bio spend on research and development?
Palisade Bio spent $10.2 million on research and development in fiscal 2025.
What are Palisade Bio's earnings per share?
Palisade Bio earned $-1.49 per diluted share in fiscal 2025, compared with $-10.92 a year earlier.
When will Palisade Bio report its next earnings?
Palisade Bio is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Palisade Bio's fiscal year end?
Palisade Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 20, 2026.